Details of the Drug Combination

General Information of Drug Combination (ID: DC5EVDK)

Drug Combination Name
Cotellic GDC-0068
Indication
Disease Entry Status REF
Neoplasms Phase 1 [1]
Component Drugs Cotellic   DMF9M57 GDC-0068   DMWBZJD
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cotellic
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [2]
Breast cancer 2C60-2C65 Phase 2 [3]
Head and neck cancer 2D42 Phase 1 [3]
Renal cell carcinoma 2C90 Phase 1 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Urothelial carcinoma 2C92.0 Phase 1 [3]
Indication(s) of GDC-0068
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [3]
Colorectal cancer 2B91.Z Phase 3 [3]
Prostate cancer 2C82.0 Phase 3 [5]
Gastric adenocarcinoma 2B72 Phase 2 [6]
Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
GDC-0068 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
GDC-0068 Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [8]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [8]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Affects Response To Substance [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01562275) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01106599) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Roche.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031868)
8 PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.